Tomomichi Ono

Kumamoto University, Kumamoto, Kumamoto Prefecture, Japan

Are you Tomomichi Ono?

Claim your profile

Publications (139)251.68 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: The frequency of Vibrio vulnificus infection is very rare and there are many questions regarding its epidemiology in Japan. To investigate the clinical course and epidemiology of V. vulnificus infection in Japan, we performed a retrospective questionnaire survey in which 1693 hospitals from all over Japan were surveyed, including advanced life saving emergency centers and dermatology institutions. Of the 1693 hospitals, we received answers from 1045. Ninety-four cases were confirmed as V. vulnificus infections during 1999 and 2003. Sixty-eight (72.3%) of the 94 patients had the septic type infection with a mortality rate of 75.0% (51/68 patients died). The prognosis of patients with the septic type was worse than that of the wound type (P < 0.001). V. vulnificus infections occurred from June to November and none occurred in winter. Many infections occurred in western Japan with the majority of infections (50/94) occurring in Kyushu. In particular, 43 infections occurred in marine coastal areas of the Ariake and Yatsushiro Seas, which have many tidelands. Seventy-seven of 89 patients (86.5%) had liver function impairment as an underlying disease, and 53 (59.6%) had liver cirrhosis, of whom nine (10.1%) suffered from liver cancer. The incidence of V. vulnificus infection was different according to districts. Geographic and climatic factors also contributed to the occurrence of V. vulnificus infection.
    The Journal of Dermatology 04/2008; 35(3):129-39. · 2.35 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In Japan, Vibrio vulnificus (V. vulnificus) infection is very rare, and most infections have occurred in Kumamoto Prefecture (1), and especially around the Ariake and Yatsushiro seas. To investigate the relationship between the occurrence of V. vulnificus infection and environmental factors, including the salinity of seawater and the amount of rain in the Ariake and Yatsushiro seas, we measured the most probable number (MPN) of V. vulnificus in seawater and sea mud. In the Ariake Sea, we also observed the temperature and salinity of seawater at one site located on an estuary where the salinity is easily affected by river water and another site located offshore where seawater is little affected by river water. Furthermore, we investigated the MPN of V. vulnificus and observed the temperature and the salinity of seawater in 25 sites in the Ariake and Yatsushiro seas from July to August 2003 and 2004. In addition, we collected data on patients with V. vulnificus infections in Kumamoto from 1990 to 2006. The MPN of V. vulnificus differed by sampling site. More V. vulnificus were detected around the inland sea than the open sea, and the increase in V. vulnificus levels was affected by rainfall around inland sea areas with many rivers. V. vulnificus increases significantly in brackish water areas, and the salinity of seawater was as important as the seawater temperature. In other words, an area's topography and amount of rain are believed to be important factors for the occurrence of V. vulnificus infection. V. vulnificus infection has been regarded as an infection of hot districts. However, the salinity of seawater may be more important than temperature for the growth of V. vulnificus. Therefore, investigating these geographical and meteorological factors can help predict areas with a higher number of V. vulnificus infection outbreaks.
    Bioscience trends 12/2007; 1(3):134-9. · 1.21 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: While many reports have outlined the health risk of chronic arsenic exposure on adult populations, relatively little is known about the effects on children. We have examined the effects of chronic arsenic exposure through consumption of contaminated groundwater among 241 children (age 4-15 yr) living in two rural villages in northern Bangladesh. The arsenic concentrations of the tubewell waters ranged from less than detection limit to 535 ng/mL, and in 72 of 241 (30%) tubewells, the water arsenic concentration exceeded 50 ng/mL, the provisional guideline of Bangladesh. Approximately half of the examined children exhibited dermatological symptoms with relatively obscured dose-response relationship; an observation suggesting that the children were no more susceptible to the dermatological effects of arsenic than the adults living in the same communities. Proportion of the children with lower BMI significantly increased with increasing arsenic exposure level; the dose-response relationship was consistently observed among the subgroups. These results suggested that while mild dermatological manifestations, potentially associated with arsenic exposure, could be found as much as half of the children, nutritional status of the children, evaluated by BMI, might be a sensitive endpoint than the dermatological manifestations among children in this area.
    Journal of Environmental Science and Health Part A 11/2007; 42(12):1835-41. · 1.14 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Herein, we describe a rare case of giant malignant peripheral nerve sheath tumor of the head in a 38-year-old Japanese man. The tumor measured 210 mm at its largest diameter and was ulcerated, hemorrhagic, multilocular and non-mobile. It should be noted that the patient stubbornly refused to see a doctor for a long time, resulting in the extreme growth of the tumor. We suspect a psychological basis for this behavior. Dermatohistopathological findings of the biopsy indicated ancient schwannoma and total excision was therefore performed. However, after 4 months, the patient developed multiple metastases and died. Post-mortem skin biopsy revealed features of malignant peripheral nerve sheath tumor. We performed immunohistochemical studies on the primary and recurrent lesions and concluded that there was a difference in the expression of Ki67 and p16. We propose that the expressions of Ki67 and p16 should be checked for all lesions of peripheral nerve sheath tumor for distinguishing benign from malignant forms.
    The Journal of Dermatology 01/2007; 33(12):865-8. · 2.35 Impact Factor
  • Nishi Nihon Hifuka 01/2007; 69(3):263-265.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The differentiation of true sentinel lymph nodes from nonsentinel lymph nodes is difficult in cases of multiple radiolabeled or dyed lymph nodes. We examined the locations of sentinel lymph nodes in melanoma and other malignant skin tumors by using dynamic lymphoscintigraphy and the single-photon-emission computed tomography/computed tomography (SPECT/CT) combined system. Sentinel lymph nodes were detected in 45 of the 53 patients examined using only the ordinary blue dye method (85%), and were detected in all 35 patients examined using the SPECT/CT method (100%). Twenty of the 35 patients mentioned above had one sentinel lymph node. Multiple sentinel lymph nodes were demonstrated in the head and neck areas using the SPECT/CT method. Significant differences (P=0.0015) in the numbers of sentinel lymph nodes were found between the blue dye method only and the SPECT/CT method in the neck area. Popliteal sentinel lymph nodes were recognized in three patients, and cubital sentinel lymph nodes were recognized in two patients. Two patients had plural regional lymph nodes: one had popliteal and groin sentinel lymph nodes, while the other had cubital and axillary sentinel lymph nodes. The probe counts of the popliteus and cubitus were significantly lower (P=0.0241) than the counts in the groin, axilla, and neck areas. Micrometastatic sentinel lymph nodes were recognized in four patients, and two patients had metastases in both sentinel and nonsentinel lymph nodes. Dynamic lymphoscintigraphy was useful when we were concerned about cubital and popliteal lymph nodes. The SPECT/CT combined system was useful in recognizing the anatomical location of sentinel lymph nodes before biopsy. The detection rate of sentinel lymph nodes using the SPECT/CT method was always better than that with the blue dye method (P=0.0197).
    International Journal of Clinical Oncology 07/2006; 11(3):214-20. · 2.17 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Germinal center-associated nuclear protein (GANP) is a newly cloned molecule that is up-regulated in the germinal center B cells. Although GANP functions in the regulation of DNA repair during replication and survival of B cells, little is known about its expression in melanocytic cells. To investigate whether GANP and phosphorylated-GANP (P-GANP) are expressed in cultured human melanocytes and melanoma cells and in benign and malignant melanocytic lesions. In addition, we aim to determine whether GANP and P-GANP are associated with malignant transformation of melanocytic lineage. GANP and P-GANP expression in cultured melanocytic cells was analyzed by immunostaining and in vitro kinase assay. GANP and P-GANP expression in melanocytic lesions was analyzed by immunohistochemistry. GANP and P-GANP were up-regulated in cultured melanoma cells compared to melanocytes. GANP and P-GANP were restricted to nucleus of melanocytes but co-expressed in cytoplasm of melanoma cells. On the other hand, GANP and P-GANP were widely expressed at various levels in melanocytic nevi and melanoma lesions with nuclear and cytoplasmic staining pattern. Melanoma cells showed a stronger intensity of GANP and P-GANP than melanocytic nevus cells, however the staining intensity in primary melanoma lesions was not associated with any clinicopathological variables. Cytoplasmic GANP and P-GANP expression was associated with MCM3 and Ki67 expression. These data suggest, for the first time, that GANP and P-GANP are up-regulated in cultured melanoma cells compared to melanocytes and also they are widely expressed in benign and malignant melanocytic tumor cells.
    Journal of Dermatological Science 05/2006; 42(1):55-63. · 3.34 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A 61-year-old woman with stage IV malignant melanoma suffered acute myocardial infarction during the third course of chemotherapy with cisplatin, dacarbazine, nimustine hydrochloride and tamoxifen citrate, despite no serious problem occurring during the first and second courses of chemotherapy. Since this patient, excluding menopause, had no significant risk factor for coronary heart disease before the start of chemotherapy, the infarction was likely to be attributable to the chemotherapy regimen. Chemotherapy should be used cautiously in patients with coronary risk factors before treatment is begun.
    Journal of Cardiology 05/2006; 47(4):191-5. · 2.57 Impact Factor
  • Hazuki Kogushi, Kiyofumi Egawa, Tomomichi Ono
    [Show abstract] [Hide abstract]
    ABSTRACT: We describe a 40-year-old male who presented with sarcoidal granulomas not only at the entry site of an industrial lubricating oil containing silicone in the right thumb, but also in a regional lymph node and at the entry points of venepuncture in both forearms. Laboratory tests and chest X-ray showed no evidence of sarcoidosis.
    Dermatology 02/2006; 212(3):250-2. · 1.69 Impact Factor
  • Internal Medicine 02/2006; 45(3):173-4. · 0.97 Impact Factor
  • Nishi Nihon Hifuka 01/2006; 68(1):46-50.
  • Nishi Nihon Hifuka 01/2006; 68(6):618-622.
  • [Show abstract] [Hide abstract]
    ABSTRACT: We present a case of a 39-year-old Japanese man with a two-year history of a mass in his suprasternal notch. Histopathologically the diagnosis was confirmed as a dermoid cyst; the cyst wall was almost normal with an epidermal structure consisting of sebaceous and apocrine glands and on the inside there were keratin materials and hair shafts. A dermoid cyst at the suprasternal notch is rare, and in an adult is the first as far as we know.
    Scandinavian Journal of Plastic and Reconstructive Surgery and Hand Surgery 02/2005; 39(1):57-9. · 0.94 Impact Factor
  • Nishi Nihon Hifuka 01/2005; 67(4):367-372.
  • Takashi IWAMOTO, Masato KIDOU, Tomomichi ONO
    Nishi Nihon Hifuka 01/2005; 67(6):566-568.
  • Tomomichi Ono, Toshiro Kageshita
    Pigment Cell Research 11/2004; 17(6):682 - 692. · 4.29 Impact Factor
  • Plastic and Reconstructive Surgery 10/2004; 114(3):833-5. · 3.33 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We used serologic screening of a cDNA expression library of human testis to identify novel cancer/testis antigens that elicit both humoral and cellular immune responses in cancer patients. Experimental Design and We identified a novel gene designated KM-HN-1 the expression of which is testis-specific among normal tissues; it contains coiled coil domains and a leucine zipper motif and encodes a putative protein consisting of 833 amino acids. KM-HN-1 expression was observed in various cancer tissues and cancer cell lines at both mRNA and protein levels. Immunofluorescence staining of an esophageal cancer cell line revealed that KM-HN-1 protein was present exclusively in the nucleus during mitosis. Recombinant KM-HN-1 protein was produced, and used for ELISA to quantitate levels of IgG antibody specific to KM-HN-1. Higher levels of IgG antibodies specific to KM-HN-1 were detected in many types and numbers of cancer patients but not in healthy donors. The CTL lines specific to KM-HN-1, generated from HLA-A*2402-positive healthy donors and cancer patients, killed human leukocyte antigen (HLA)-A24-positive cancer cells expressing KM-HN-1 but not cell lines that did not express either KM-HN-1 or HLA-A24. We identified a novel cancer/testis antigen, KM-HN-1, which elicited humoral immune responses in patients with various types of cancer. Furthermore, KM-HN-1-specific CTLs could be generated from both healthy donors and cancer patients, which indicated that KM-HN-1 can be a candidate for an ideal target for cancer immunotherapy.
    Clinical Cancer Research 10/2004; 10(18 Pt 1):6047-57. · 8.19 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We reported recently the novel tumor marker glypican-3 (GPC3) for hepatocellular carcinoma. In the present study, we investigated the expression of GPC3 in human melanoma cell lines and tissues and asked whether GPC3 could be a novel tumor marker for melanoma. Expression of GPC3 mRNA and protein was investigated in human melanoma cell lines and tissues using reverse transcription-PCR and immunohistochemical analysis. Secreted GPC3 protein was quantified using ELISA in culture supernatants of melanoma cell lines and in sera from 91 patients with melanoma and 28 disease-free patients after surgical removal of primary melanoma. All of the subjects were Japanese nationals. In >80% of melanoma and melanocytic nevus, there was evident expression of GPC3 mRNA and protein. Furthermore, GPC3 protein was evidenced in sera of 39.6% (36 of 91) of melanoma patients but not in sera from subjects with large congenital melanocytic nevus (0 of 5) and from healthy donors (0 of 60). Twenty-seven of 36 serum GPC3-positive patients were negative for both serum 5-S-cysteinyldopa and melanoma-inhibitory activity, well-known tumor markers for melanoma. The positive rate of serum GPC3 (39.6%) was significantly higher than that of 5-S-cysteinyldopa (26.7%) and of melanoma-inhibitory activity (20.9%). Surprisingly, we detected serum GPC3 even in patients with stage 0 in situ melanoma. The positive rate of serum GPC3 at stage 0, I, and II (44.4%, 40.0%, and 47.6%) was significantly higher than that of 5-S-cysteinyldopa (0.0%, 8.0%, and 10.0%). Also observed was the disappearance of GPC3 protein in sera from 11 patients after surgical removal of the melanoma. GPC3 is apparently a novel tumor marker useful for the diagnosis of melanoma, especially in early stages of the disorder.
    Clinical Cancer Research 10/2004; 10(19):6612-21. · 8.19 Impact Factor
  • The Journal of Dermatology 02/2004; 31(1):73-5. · 2.35 Impact Factor

Publication Stats

1k Citations
251.68 Total Impact Points


  • 1991–2008
    • Kumamoto University
      • • Graduate School of Medical Sciences
      • • Department of Developmental Genetics
      • • Department of Obstetrics and Gynecology
      • • School of Medicine
      • • Department of Microbiology
      Kumamoto, Kumamoto Prefecture, Japan
  • 2003
    • Gifu University
      Gihu, Gifu, Japan
  • 2000
    • University of California, Berkeley
      • Department of Molecular and Cell Biology
      Berkeley, MO, United States
  • 1999
    • New York Medical College
      • Department of Microbiology and Immunology
      New York City, New York, United States